Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07477522

Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinical Study

Led by West China Hospital · Updated on 2026-03-17

25

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Cancer is a major global health challenge, with over 19 million new cases and nearly 10 million deaths worldwide annually, most being solid tumors such as lung cancer. Late-stage solid tumors have limited treatment options due to metastasis, treatment toxicities, and resistance to current therapies. Dietary fiber is emerging as a promising adjunct because it may improve immune responses and treatment outcomes by positively affecting gut microbiota and metabolism. This study evaluates a high-insoluble-fiber diet (more than 21 grams per day) in patients with solid tumors to see how it changes gut bacteria, metabolites, and immune system markers. Participants will follow this diet while researchers assess its safety and tolerability over six weeks. The study will also track treatment responses and quality of life up to one year. Participants will be monitored through laboratory tests, nutritional assessments, and immune profiling during the treatment period. Researchers will measure safety, tumor response rates, and duration of response. The study aims to clarify how dietary fiber affects cancer progression and treatment effectiveness, with follow-up lasting up to one year from enrollment.

CONDITIONS

Brief Title

Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinical Study

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed written informed consent before any study procedures.
  • Males or females aged 18 to 80 years.
  • Diagnosed with solid tumors confirmed by pathological tissue biopsy.
  • At least one measurable lesion by RECIST v1.1 criteria (excluding lesions previously treated locally).
  • ECOG Performance Status score of 0 to 1.
  • Nutritional Risk Screening 2002 score less than 3.
  • Body Mass Index 18.5 or higher (adjustable as needed).
  • Able to eat orally or via feeding tube and tolerate enteral nutrition.
  • Adequate organ function based on specified laboratory tests.
  • Women of child-bearing potential must use contraception and have negative pregnancy test before treatment.
  • Subjects at risk of pregnancy must use effective contraception during treatment and specified time after.
Not Eligible

You will not qualify if you...

  • Cognitive impairment or mental illness preventing understanding of the study.
  • Central nervous system or meningeal metastases.
  • Moderate or severe symptomatic ascites requiring recent paracentesis.
  • Uncontrolled or moderate to severe pleural or pericardial effusion.
  • Severe gastrointestinal conditions such as severe diarrhea, vomiting, malabsorption, intestinal obstruction, fistulas, or recent high-grade bleeding.
  • Known allergy to study drug ingredients.
  • Poorly controlled diabetes or hypertension.
  • Severe cardiovascular or cerebrovascular diseases including recent stroke or heart attack.
  • Pregnant or breastfeeding women.
  • Other conditions deemed inappropriate by the investigator for enrollment.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 6 weeks

Participants follow a high-fibre diet with more than 21 grams per day of insoluble fibre to assess its effects on gut microbiota, metabolism, and immune microenvironment in solid tumor patients.

Trial Site Locations

Total: 1 location

1

West China Hospital

Chengdu, Sichuan, China

Actively Recruiting

Loading map...

Research Team

J

Jingwen Wei

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Study of ABT-301 With Tislelizumab and Bevacizumab in pMMR/N...

Colorectal Cancer (Diagnosis)

Actively Recruiting

15 locations

ColoSense Post Approval Study for Colorectal Cancer Detectio...

Colorectal Cancer (Diagnosis)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here